View In Article
View In Article | Cross Ref
View In Article | Cross Ref
View In Article
View In Article | Cross Ref
View In Article | Cross Ref
View In Article | Cross Ref
View In Article | Cross Ref
View In Article | Cross Ref
View In Article | Cross Ref
View In Article | Cross Ref
View In Article | Cross Ref
department patients with acute severe pain. In (eds): Research forum abstracts. pp. 4


27. Alaska State Board of Nursing advisory opinion. www.commerce.state.ak.us/dnn/Portals/5/pub/NUR_Advisory_Ketamine_Administration.pdf (accessed 2015 May 13)


92. Bijur P.E., Kenny M.K., and Gallagher E.J.: Intravenous morphine at 0.1 mg/kg is not effective for controlling severe acute pain in the majority of patients. Ann Emerg Med


168. CONSORT:  http://www.consort-statement.org/consort-2010


211. Ead 2003.


244. Folts 1975.


View In Article

View In Article | Cross Ref

View In Article

View In Article


View In Article | Cross Ref

View In Article | Cross Ref

296. Grading quality of evidence and strength of recommendations. BMJ 2004; 328:
View In Article

View In Article | Cross Ref

View In Article

View In Article

View In Article

View In Article
View In Article
View In Article
View In Article


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article


View In Article


View In Article | Cross Ref


View In Article


View In Article


View In Article | Cross Ref


View In Article | Cross Ref


MacDonald N., and MacLeod S.M.: Has the time come to phase out codeine? CMAJ 2010 Nov 23; 182: pp. 1825


Marchertiene 2008.

Marchertiene 2008.

Marchertiene 2008.

Marchertiene 2008.

Marchertiene 2008.

Marchertiene 2008.

Marchertiene 2008.


patients receiving opioid therapy. JAMA Intern Med 2015 Apr; 175: pp. 608-615


View In Article | Cross Ref

View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


View In Article | Cross Ref


553. Newton 2008. View In Article


   View In Article | Cross Ref

   View In Article | Cross Ref

   View In Article

   CrossRef Google Scholar

   View In Article

   View In Article | Cross Ref


   View In Article | Cross Ref

   View In Article

   View In Article | Cross Ref


   View In Article | Cross Ref


View In Article | Cross Ref

View In Article | Cross Ref

View In Article | Cross Ref

View In Article | Cross Ref

View In Article | Cross Ref

View In Article


View In Article | Cross Ref

View In Article | Cross Ref

View In Article


View In Article | Cross Ref

View In Article
dexketoprofen in acute migraine attack in the emergency department: a randomised
View In Article | Cross Ref

View In Article | Cross Ref

View In Article | Cross Ref

735. Tziavrangos E., Schug S.A.: Clinical pharmacology: other adjuvants. In: Macyntyre

736. Tziavrangos E., Schug S.A.: Clinical Pharmacology: other adjuvants. In: Macyntyre

737. Tziavrangos E., and Schug S.A.: Clinical pharmacology: other adjuvants. In
View In Article

Macyntyre P.E., Walker S.M., and Rowbotham D.J. (eds): Clinical pain management
View In Article

739. U.S. Drug Enforcement Administration website. Substance Abuse and Mental
Health Services Administration. The TEDS report: substance abuse treatment admissions
involving abuse of pain relievers: 1998 and 2008. Available at:
View In Article

740. U.S. Food and Drug Administration (FDA) : FDA drug safety communication:
prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed
warning will highlight potential for severe liver failure.
https://www.fda.gov/Drugs/DrugSafety/ucm239821.htm
View In Article

741. U.S. Food and Drug Administration website. Outpatient prescription opioid
utilization in the U.S., years 2000-2009. Available at:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drug
s/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf. Accessed
November 28, 2015.
View In Article

742. Uprety D, Baber A, Foy M. Ketamine infusion for sickle cell pain crisis refractory
[PubMed]

743. Uprety D, Baber A, Foy M. Ketamine infusion for sickle cell pain crisis refractory
[PubMed]
    View In Article | Cross Ref

    View In Article

    View In Article | Cross Ref

    View In Article | Cross Ref

    View In Article | Cross Ref

    View In Article | Cross Ref

    View In Article | Cross Ref

    View In Article

    View In Article | Cross Ref

    View In Article | Cross Ref

    View In Article | Cross Ref

    View In Article
762. Ward 2003. View In Article


    View In Article | Cross Ref
    View In Article | Cross Ref
    View In Article | Cross Ref
    View In Article | Cross Ref
    View In Article | Cross Ref
    View In Article | Cross Ref
    View In Article | Cross Ref
    View In Article | Cross Ref

View In Article | Cross Ref


View In Article | Cross Ref